Regression of metastatic melanoma by targeting cancer stem cells

Oncotarget

Volumn 3, Issue 1, 2012, Pages 22-30

  Schlaak, Max ^a   Schmidt, Patrick ^a,b   Bangard, Christopher ^a   Kurschat, Peter ^a   Mauch, Cornelia ^a   Abken, Hinrich ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b EPFL   (Switzerland)

Author keywords

Cancer stem cell; CD20; Melanoma; Rituximab

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; DACARBAZINE; MONOCLONAL ANTIBODY; RITUXIMAB;

AGED; ARTICLE; CANCER STEM CELL; CASE REPORT; DRUG EFFECT; FOOT; HUMAN; IMMUNOLOGY; MALE; MELANOMA; MOLECULARLY TARGETED THERAPY; PATHOLOGY; REMISSION; SKIN TUMOR; TUMOR VOLUME;

AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FOOT; HUMANS; MALE; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; REMISSION INDUCTION; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84863216083     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.437     Document Type: Article

References (16)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med 1997; 3: 730-737.
2. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med 2011; 17: 313-319.
3. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-9337.
4. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature 2008; 451: 345-349.
5. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, Longaker MT, Weissman IL. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133-137.
6. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
7. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010; 18: 510-523.
8. Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006; 24: 2603-2610.
9. Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc. Natl. Acad. Sci. U.S.A 2011; 108: 2474-2479.
10. Schmidt P, Abken H. The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget 2011; 2: 313-320.
11. Trcka J, Kämpgen E, Becker JC, Schwaaf A, Bröcker EB. [Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)]. Hautarzt 1998; 49: 17-22.
12. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu. Rev. Med. 2008; 59: 237-250.
13. Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2011; 2: 684-694.
14. Di J, Duiveman-de Boer T, Figdor CG, Torensma R. Eradicating cancer cells: struggle with a chameleon. Oncotarget 2011; 2: 99-101.
15. Schnaiter A, Stilgenbauer S. Refractory chronic lymphocytic leukemia--new therapeutic strategies. Oncotarget 2010; 1: 472-482.
16. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010; 1: 563-577.